Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Antibody Actions01:26

Antibody Actions

3.9K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.9K
Hybridoma Technology01:31

Hybridoma Technology

13.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.

EMBO molecular medicine·2026
Same author

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Blood neoplasia·2026
Same author

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

HemaSphere·2026
Same author

C1q-targeting bispecific antibodies bypass Fc to trigger complement activation and receptor clustering agonism.

Molecular immunology·2026
Same author

Novel vanadium-dependent haloperoxidases from macroalgae and their expression in response to biotic and abiotic stressors in <i>Saccharina latissima</i>.

Marine life science & technology·2026
Same author

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Methods in molecular biology (Clifton, N.J.)·2026

Related Experiment Video

Updated: Apr 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Complement in antibody-based tumor therapy.

Stefanie Derer1, Frank J Beurskens2, Thies Rosner1

  • 1Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts University and University Hospital Schleswig-Holstein, Kiel, Germany.

Critical Reviews in Immunology
|June 19, 2014
PubMed
Summary
This summary is machine-generated.

Monoclonal antibodies can fight tumors via antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). While ADCC

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Related Experiment Videos

Last Updated: Apr 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K

Area of Science:

  • Immunology and Oncology
  • Therapeutic Antibody Development

Background:

  • Monoclonal antibodies are key cancer therapeutics, leveraging Fc region interactions to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
  • Clinical evidence supports ADCC's role in therapeutic antibody efficacy, linked to Fcγ receptor polymorphisms.
  • The clinical significance of CDC in antibody therapy remains uncertain due to tumor cell complement-regulatory proteins and some antibodies' limited CDC capacity.

Purpose of the Study:

  • To review strategies aimed at enhancing complement-dependent cytotoxicity (CDC) for improved therapeutic antibody efficacy.
  • To highlight the gap in clinical validation for CDC-enhancing antibodies and CDC-optimizing approaches.

Main Methods:

  • Review of strategies to improve antibody-initiated complement cascade activation.
  • Analysis of approaches targeting tumor cell resistance mechanisms to complement.

Main Results:

  • In vitro and murine models show therapeutic benefits for both antibody and tumor-focused CDC-enhancement strategies.
  • CDC-enhanced antibodies have not yet undergone clinical testing.
  • Human data on the clinical potential of CDC-optimizing approaches are lacking.

Conclusions:

  • The clinical impact of complement activation, particularly via CDC, in therapeutic antibody efficacy requires further elucidation.
  • Clinical trials incorporating novel complement-enhancing molecules are necessary to validate the potency of CDC in cancer therapy.